Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394632 | 0.94 | ALDH1A1 (0.33) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL1012045 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL1352707 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL6472790 | 0.79 | TSHR (0.39) | ALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL15800756 | 0.75 | ALDH1A1 (0.35) | ALDH1A1TSHRARG2 | |
| SCHEMBL31040516 | 0.73 | LMNA (0.42) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL31040519 | 0.73 | LMNA (0.42) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL1352447 | 0.73 | ALDH1A1 (0.38) | ALDH1A1TSHR | |
| SCHEMBL15694681 | 0.73 | ALDH1A1 (0.37) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL3871791 | 0.73 | ALDH1A1 (0.37) | ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016865-B2 | Methods and pharmaceutical compositions for treating candida auris in blood | CORMEDIX INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3313857-B1 | POLYMER-CYCLODEXTRIN-LIPID CONJUGATES | WU NIAN (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10835608-B2 | Polymer-carbohydrate conjugates for drug delivery technology | LIPOSEUTICALS INC | 2020-11-17 | — | — | US | disclosed |
| EP-3727393-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANDIDA AURIS IN BLOOD | CorMedix Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3077006-B1 | POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY | WU NIAN (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20190192529-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANDIDA AURIS IN BLOOD | CORMEDIX INC. | 2019-06-27 | — | — | US | disclosed |
| US-10064954-B2 | Polymer-cyclodextrin-lipid conjugates | LIPOSEUTICALS INC | 2018-09-04 | — | — | US | disclosed |
| EP-2673000-B1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | WU NIAN (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3313857-A1 | POLYMER-CYCLODEXTRIN-LIPID CONJUGATES | Wu, Nian (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20160375150-A1 | POLYMER-CYCLODEXTRIN-LIPID CONJUGATES | LIPOSEUTICALS INC | 2016-12-29 | — | — | US | disclosed |
| EP-2673000-A2 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | Wu, Nian (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013003306-A1 | PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION | WU NIAN (US) | 2013-01-03 | — | — | WO | disclosed |
| US-20130004592-A1 | PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION | LIPOSEUTICALS, INC. | 2013-01-03 | — | — | US | disclosed |
| US-8304565-B2 | PEG-lipid conjugates for liposomes and drug delivery | BIOZONE LABORATORIES INC. | 2012-11-06 | — | — | US | disclosed |
| WO-2012109112-A2 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | WU NIAN (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012109052-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | WU NIAN (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202979-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPOSEUTICALS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202890-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | WU NIAN (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011139343-A2 | AMINO ACID LINKED PEG-LIPID CONJUGATES | WU NIAN (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20100076209-A1 | PEG-lipid conjugates for liposomes and drug delivery | BIOZONE LABORATORIES INC. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076209-A1 | PEG-lipid conjugates for liposomes and drug delivery | DAGLA, DAGLB, DGKG | ALDH1A1 2787/4885TSHR 2520/4885SMN1; SMN2 4412/4885 |
| US-10835608-B2 | Polymer-carbohydrate conjugates for drug delivery technology | LIPC, FABP4, CETP | ALDH1A1 2457/4885TSHR 2812/4885SMN1; SMN2 3875/4885 |
| US-20130004592-A1 | PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION | LIPC, CETP, UGCG | ALDH1A1 2204/4885TSHR 4218/4885SMN1; SMN2 2315/4885 |
| US-10064954-B2 | Polymer-cyclodextrin-lipid conjugates | CETP, FABP4, PLIN3 | ALDH1A1 1058/4885TSHR 3583/4885SMN1; SMN2 4405/4885 |
| US-20120202890-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPC, FUT6, UGCG | ALDH1A1 873/4885TSHR 3962/4885SMN1; SMN2 4271/4885 |
| US-20120202979-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPC, FUT6, UGCG | ALDH1A1 873/4885TSHR 3962/4885SMN1; SMN2 4271/4885 |
| US-20160375150-A1 | POLYMER-CYCLODEXTRIN-LIPID CONJUGATES | CETP, FADS2, FABP4 | ALDH1A1 1355/4885TSHR 3545/4885SMN1; SMN2 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.